| What it is | A combination of atomoxetine and oxybutynin—two medications—taken at night to increase upper airway muscle activity and reduce OSA symptoms. | Pressurized air is delivered through a nasal or face mask while sleeping to keep the airway open. | A removable oral appliance worn at night moves the lower jaw forward to widen the airway and prevent airway collapse. | Current guideline-based therapy uses PAP as the first-line, with oral appliances (dental devices) as an accepted alternative for adults with OSA who cannot tolerate or prefer not to use PAP. |
|---|
| Role in trial | Randomized arm; evaluated as an investigational medication-based approach for OSA. | Randomized arm; serves as an established comparator for OSA treatment. | Randomized arm; compared as a device-based alternative to PAP and medication. | Current-care column. Draws from clinical practice guidelines and is not a randomized arm in this trial. |
|---|
| Primary use | Increases tone in upper airway muscles via medication, aiming to reduce the number of apneas and improve sleep quality. | Keeps upper airway open during sleep by delivering continuous or variable pressurized air. | Advances the lower jaw to reduce airway collapse during sleep, lowering OSA severity. | PAP is recommended as first-line for symptomatic OSA. Oral appliances are used if patients do not tolerate or decline PAP. |
|---|
| How it is given or performed | Participants take atomoxetine and oxybutynin as prescribed, usually before sleep, to achieve effect overnight. | Participants use a PAP machine with a nasal or facial mask nightly during sleep. | Participants wear a custom-fitted oral appliance every night during sleep to reposition the jaw. | PAP therapy is delivered nightly by mask. Oral appliances are used if PAP is declined or not tolerated, following dental evaluation and fitting. |
|---|
| Evidence status | Small randomized trials show this drug combination can reduce OSA severity in the short term but long-term effectiveness, safety, and quality-of-life impact remain under investigation. | Decades of high-quality evidence shows PAP therapy significantly improves OSA severity, symptoms, quality of life, and reduces related risks for most adults who adhere to therapy. | High-quality evidence supports oral appliances as effective for many adults with OSA, especially those with mild to moderate disease or who cannot tolerate PAP. They improve symptoms and reduce OSA events, though typically less than PAP. | Guidelines consider PAP the most effective non-surgical therapy for most adults with symptomatic OSA. Oral appliances are considered effective in selected patients. No guidelines endorse drug therapy at this time. |
|---|
| Important limitations | Long-term safety, tolerability, and real-world use are unknown. Excludes patients with certain heart conditions, glaucoma, liver disease, depression, or medication interactions. | Adherence is a major limitation. Many patients struggle to use PAP regularly due to discomfort, mask leaks, or noise. Effectiveness depends on nightly use. | Oral appliances may be less effective for severe OSA, require dental fitting, and may cause jaw discomfort or dental side effects. Not suitable for those with poor dentition or jaw problems. | Practical barriers to PAP include comfort, cost, and adherence. Oral appliance effectiveness is limited in severe OSA. Medication-based approaches have insufficient evidence and are not recommended outside trials. |
|---|